ONCY · Oncolytics Biotech Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| R&D | $2.80M | - | - | - |
| SG&A | $2.22M | - | - | - |
| Total Operating Expenses | $5.02M | - | - | - |
| D&A | $19.0K | - | - | - |
| Operating Income | ($5.02M) | - | - | - |
| Interest Expense | - | - | - | - |
| Income Tax | - | - | - | - |
| Net Income | ($4.71M) | - | - | - |
| EPS - Basic | ($0.06) | - | - | - |
| EPS - Diluted | ($0.06) | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Cash & Equivalents | $5.49M | $5.20M | $11.08M | $26.40M |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | $2.68M | $3.50M | $756.0K | - |
| Current Assets | $7.49M | $6.84M | $12.44M | - |
| Total Assets | $8.16M | $7.58M | $13.42M | - |
| Current Liabilities | $5.42M | $6.10M | $4.88M | - |
| Long-term Debt | - | - | - | - |
| Total Liabilities | $13.29M | $11.38M | $10.12M | - |
| Stockholders' Equity | $3.73M | ($3.80M) | $3.30M | $19.60M |
| Retained Earnings | ($438.74M) | ($429.50M) | ($400.74M) | - |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Operating Cash Flow | ($4.73M) | - | - | - |
| Investing Cash Flow | ($1.0K) | - | - | - |
| Financing Cash Flow | $4.18M | - | - | - |
| CapEx | $1.0K | - | - | - |
| Free Cash Flow | ($4.73M) | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | - | - | - | - |
| EBITDA margin | - | - | - | - |
| Net margin | - | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | 1.00 | - | - | - |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | - | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -57.7% | - | - | - |
| Return on equity | -126.5% | - | - | - |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | 1.38 | 1.12 | 2.55 | - |
| Quick ratio | 1.38 | 1.12 | 2.55 | - |
| Cash ratio | 1.01 | 0.85 | 2.27 | - |
| Leverage | ||||
| Debt / Equity | - | - | - | - |
| Debt / Assets | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | - | - | - | - |
| Equity multiplier | 2.19 | -2.00 | 4.07 | - |
| Liabilities / Assets | 1.63 | 1.50 | 0.75 | - |
| Efficiency | ||||
| Asset turnover | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | 19.3x | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - |
| Net income growth (YoY) | - | - | - | - |
| EPS growth (YoY) | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | - | - | -83.2% | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ONCOLYTICS BIOTECH INC against the 5 most active filers in the same SIC group.